Current and future therapies for small cell lung carcinoma

Table 1 Pivotal clinical trials evaluating the efficacy of FDA/NMPA-approved agents for SCLC

Drug Name	Trial number	Phase	Patients	Strategy	Drugs	N	Median OS	Median PFS	Status	Indication
Atezolizumab	NCT02763579	3	ES-SCLC	PD-L1 inhibitor + Chemo	Atezolizumab + Chemo vs. Chemo	201 vs. 202	12.3 vs. 10.3 months	5.2 vs. 4.3 months	FDA approved	First line
Tislelizumab	NCT04005716	3	ES-SCLC	PD-L1 inhibitor + Chemo	Tislelizumab + Chemo vs. Chemo	457	15.5 months vs. 13.5 months	4.8 months vs. 4.3 months	NMPA approved	First line
Pembrolizumab	NCT03066778	3	ES-SCLC	Chemo + PD-1 inhibitor	Pembrolizumab + Chemo vs. Chemo	228 vs. 225	10.8 vs. 9.7 months	4.5 vs. 4.3 months	FDA approved	Second line
Adebrelimab	NCT03711305	3	ES-SCLC	Chemo + PD-L1 inhibitor	Chemo + Adebrelimab vs. Chemo	230 vs. 232	15.3 vs. 12.8 months	5.8 vs. 5.6 months	NMPA approved	First line
Serplulimab	NCT04063163	3	ES-SCLC	Chemo + PD-1 inhibitor	Chemo + Serplulimab vs. Chemo	389 vs. 196	15.4 vs. 10.9 months	5.7 vs. 4.3 months	NMPA approved	First line
Anlotinib + Benmelstobart	NCT04234607	3	ES-SCLC	Chemo + anti-Angiogenesis + PD-L1 inhibitor	Chemo + Anlotinib + Benmelstobart vs. Chemo	246 vs. 247	19.3 vs. 11.9 months	6.9 vs. 4.2 months	NMPA approved	First line
Toripalimab	NCT04012606	3	ES-SCLC	Chemo + PD-1 inhibitor	Chemo + Toripalimab vs. Chemo	213 vs. 219	14.6 vs. 13.3 months	5.8 vs. 5.6 months	NMPA approved	First line

Abbreviations: Chemo, chemotherapy; NCT, ClinicalTrials.gov identifier; FDA, U.S. Food and Drug Administration; NMPA, National Medical Products Administration; ORR, objective response rate; OS, overall survival; PD‐1, programmed cell death protein 1; PD‐L1, programmed death‐ligand 1; PFS, progression‐free survival

ISSN: 1756-8722